SGMO – Sangamo Therapeutics, Inc.
SGMO — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
10.46
Margin Of Safety %
Put/Call OI Ratio
0.39
EPS Next Q Diff
EPS Last/This Y
EPS This/Next Y
0.26
Price
0.14
Target Price
3.75
Analyst Recom
2
Performance Q
-49.76
Upside
N/A
Beta
1.07
Ticker: SGMO
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-04-23 | SGMO | 0.2549 | 0.32 | 0.65 | 69468 |
| 2026-04-24 | SGMO | 0.1894 | 0.32 | 1.31 | 69579 |
| 2026-04-27 | SGMO | 0.2129 | 0.34 | 0.23 | 71690 |
| 2026-04-28 | SGMO | 0.2043 | 0.34 | 0.46 | 71884 |
| 2026-04-29 | SGMO | 0.1326 | 0.34 | 0.05 | 72002 |
| 2026-04-30 | SGMO | 0.1209 | 0.33 | 0.04 | 72332 |
| 2026-05-01 | SGMO | 0.1357 | 0.34 | 0.32 | 71750 |
| 2026-05-04 | SGMO | 0.1774 | 0.33 | 0.02 | 72818 |
| 2026-05-05 | SGMO | 0.1131 | 0.33 | 0.00 | 73392 |
| 2026-05-06 | SGMO | 0.1212 | 0.32 | 0.00 | 73019 |
| 2026-05-07 | SGMO | 0.1017 | 0.32 | 0.00 | 73019 |
| 2026-05-08 | SGMO | 0.115 | 0.32 | 0.00 | 73019 |
| 2026-05-11 | SGMO | 0.1205 | 0.32 | 0.00 | 73019 |
| 2026-05-12 | SGMO | 0.138 | 0.32 | 0.00 | 73019 |
| 2026-05-13 | SGMO | 0.14 | 0.32 | 0.00 | 73019 |
| 2026-05-14 | SGMO | 0.1381 | N/A | N/A | 0 |
| 2026-05-15 | SGMO | 0.1334 | N/A | N/A | 0 |
| 2026-05-18 | SGMO | 0.1239 | 0.32 | 999.99 | 72976 |
| 2026-05-19 | SGMO | 0.1403 | 0.32 | 999.99 | 72976 |
| 2026-05-20 | SGMO | 0.157 | 0.32 | 999.99 | 72976 |
| 2026-05-21 | SGMO | 0.159 | 0.39 | 0.00 | 61904 |
| 2026-05-22 | SGMO | 0.1728 | 0.39 | 0.00 | 61904 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-04-23 | SGMO | 0.25 | 50.0 | - | -0.26 |
| 2026-04-24 | SGMO | 0.19 | 50.0 | - | -0.26 |
| 2026-04-27 | SGMO | 0.21 | 50.0 | - | -0.26 |
| 2026-04-28 | SGMO | 0.20 | 50.0 | - | -0.26 |
| 2026-04-30 | SGMO | 0.12 | 50.0 | - | -0.26 |
| 2026-05-01 | SGMO | 0.13 | 50.0 | - | -0.26 |
| 2026-05-04 | SGMO | 0.18 | 50.0 | - | -0.26 |
| 2026-05-05 | SGMO | 0.18 | 50.0 | - | -0.26 |
| 2026-05-06 | SGMO | 0.18 | 50.0 | - | -0.26 |
| 2026-05-07 | SGMO | 0.13 | 50.0 | - | -0.26 |
| 2026-05-08 | SGMO | 0.10 | 50.0 | - | -0.26 |
| 2026-05-11 | SGMO | 0.12 | 50.0 | - | -0.26 |
| 2026-05-12 | SGMO | 0.12 | 50.0 | - | -0.26 |
| 2026-05-13 | SGMO | 0.14 | 50.0 | - | -0.26 |
| 2026-05-14 | SGMO | 0.14 | 50.0 | - | -0.26 |
| 2026-05-15 | SGMO | 0.14 | 50.0 | - | -0.26 |
| 2026-05-18 | SGMO | 0.14 | 50.0 | - | -0.26 |
| 2026-05-19 | SGMO | 0.14 | 50.0 | - | -0.26 |
| 2026-05-20 | SGMO | 0.14 | 50.0 | - | -0.26 |
| 2026-05-21 | SGMO | 0.14 | 50.0 | - | -0.26 |
| 2026-05-22 | SGMO | 0.14 | 50.0 | - | -0.26 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-04-23 | SGMO | -4.46 | 0.07 | 9.17 |
| 2026-04-24 | SGMO | -8.96 | 0.07 | 9.17 |
| 2026-04-27 | SGMO | -8.96 | -0.28 | 10.46 |
| 2026-04-28 | SGMO | -8.96 | -0.28 | 10.46 |
| 2026-04-29 | SGMO | -8.96 | -0.28 | 10.46 |
| 2026-04-30 | SGMO | -8.96 | -0.28 | 10.46 |
| 2026-05-01 | SGMO | -8.96 | -0.28 | 10.46 |
| 2026-05-04 | SGMO | -8.96 | -0.24 | 10.46 |
| 2026-05-05 | SGMO | -8.96 | -0.24 | 10.46 |
| 2026-05-06 | SGMO | -8.96 | -0.24 | 10.46 |
| 2026-05-07 | SGMO | -8.96 | -0.24 | 10.46 |
| 2026-05-08 | SGMO | -8.96 | -0.24 | 10.46 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
-0.07
Avg. EPS Est. Next Quarter
-0.07
Insider Transactions
-8.96
Institutional Transactions
-0.24
Beta
1.07
Average Sales Estimate Current Quarter
40
Average Sales Estimate Next Quarter
11
Fair Value
Quality Score
3
Growth Score
32
Sentiment Score
15
Actual DrawDown %
98.9
Max Drawdown 5-Year %
-99.2
Target Price
3.75
P/E
Forward P/E
PEG
P/S
1.86
P/B
P/Free Cash Flow
EPS
-0.44
Average EPS Est. Cur. Y
-0.26
EPS Next Y. (Est.)
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-310.81
Relative Volume
Return on Equity vs Sector %
834.5
Return on Equity vs Industry %
850.1
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
-0.07
EBIT Estimation
No data found for SGMO
Sangamo Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 142
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; small fiber neuropathy for chronic neuropathic pain, and prion disease; Phase 1/2 clinical trial to evaluate the safety and tolerability of the investigational genetically modified cell therapy TX200 in patients undergoing a kidney transplant.; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; giroctocogene fitelparvovec, a Phase 3 study to evaluate the clinical efficacy and safety of giroctocogene fitelparvovec gene therapy in adult male with moderately severe or severe hemophilia A. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Genentech, Inc.; Astellas Gene Therapies, Inc.; Capsid Delivery License Agreement with Eli Lilly and Company; Alexion Pharmaceuticals, Inc. ALS and Frontotemporal Lobar Degeneration; Takeda Huntington's Disease; and other areas, such as plant agriculture and research reagents, including the production of transgenic animals and cell-line engineering with Corteva AgriScience and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California.
SGMO
Latest News
—
Caricamento notizie per SGMO…
stock quote shares SGMO – Sangamo Therapeutics, Inc. Stock Price stock today
news today SGMO – Sangamo Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch SGMO – Sangamo Therapeutics, Inc. yahoo finance google finance
stock history SGMO – Sangamo Therapeutics, Inc. invest stock market
stock prices SGMO premarket after hours
ticker SGMO fair value insiders trading